• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Initial response of renal cell carcinoma to vemurafenib in a patient treated for metastatic melanoma.

作者信息

Hosier Gregory W, Roberts Matthew T

机构信息

Department of Urology, Queen's University, Kingston, ON, Canada.

Division of Urology, Department of Surgery, University of Ottawa, Ottawa, ON, Canada.

出版信息

Can Urol Assoc J. 2016 Sep-Oct;10(9-10):E306-E308. doi: 10.5489/cuaj.3652. Epub 2016 Sep 13.

DOI:10.5489/cuaj.3652
PMID:27695585
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5028215/
Abstract
摘要

相似文献

1
Initial response of renal cell carcinoma to vemurafenib in a patient treated for metastatic melanoma.一名接受转移性黑色素瘤治疗的患者中肾细胞癌对维莫非尼的初始反应。
Can Urol Assoc J. 2016 Sep-Oct;10(9-10):E306-E308. doi: 10.5489/cuaj.3652. Epub 2016 Sep 13.
2
Long Term Survival and Continued Complete Response of Vemurafenib in a Metastatic Melanoma Patient with BRAF V600K Mutation.维莫非尼在一名BRAF V600K突变的转移性黑色素瘤患者中的长期生存及持续完全缓解
Case Rep Oncol Med. 2016;2016:2672671. doi: 10.1155/2016/2672671. Epub 2016 Feb 18.
3
Vemurafenib: in unresectable or metastatic melanoma.威罗菲尼：适用于不可切除或转移性黑色素瘤。
BioDrugs. 2012 Oct 1;26(5):325-34. doi: 10.2165/11209860-000000000-00000.
4
Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.接受基于白细胞介素-2免疫疗法治疗后出现反应的转移性黑色素瘤或肾细胞癌患者的复发模式及对再治疗的反应
Cancer J Sci Am. 1998 Mar-Apr;4(2):86-93.
5
Development of Acute Vogt-Koyanagi-Harada-like Syndrome during the Treatment Course with Vemurafenib for Metastatic Melanoma.维莫非尼治疗转移性黑色素瘤过程中出现急性 Vogt-Koyanagi-Harada 样综合征。
Ocul Immunol Inflamm. 2020 Apr 2;28(3):505-508. doi: 10.1080/09273948.2019.1597896. Epub 2019 Jun 4.
6
Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.维莫非尼治疗3219例BRAF突变阳性转移性黑色素瘤患者的开放标签、多中心安全性研究：2年随访数据及长期缓解者分析
Eur J Cancer. 2017 Jul;79:176-184. doi: 10.1016/j.ejca.2017.04.007. Epub 2017 May 11.
7
Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data.维莫非尼治疗43例BRAF突变转移性黑色素瘤患者的疗效。单机构回顾性分析，早期真实生存数据。
Pathol Oncol Res. 2019 Jan;25(1):45-50. doi: 10.1007/s12253-017-0324-1. Epub 2017 Sep 29.
8
[Breast lesions of a metastatic melanoma on a radiotherapy territory: Treatment by vemurafenib and carcinologic surgery].[放射治疗区域内转移性黑色素瘤的乳腺病变：维莫非尼治疗及肿瘤外科手术]
Ann Chir Plast Esthet. 2016 Feb;61(1):69-75. doi: 10.1016/j.anplas.2014.09.013. Epub 2014 Oct 28.
9
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.维莫非尼治疗 BRAF(V600) 突变转移性黑色素瘤患者：一项开放性、多中心、安全性研究。
Lancet Oncol. 2014 Apr;15(4):436-44. doi: 10.1016/S1470-2045(14)70051-8. Epub 2014 Feb 27.
10
Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.在现实环境中接受维莫非尼治疗的BRAF V600E突变型黑色素瘤脑转移患者的治疗模式和结局
Cancer Med. 2015 Aug;4(8):1205-13. doi: 10.1002/cam4.475. Epub 2015 May 20.

本文引用的文献

1
A Rare Finding of a BRAF Mutation in Renal Cell Carcinoma with Response to BRAF-Directed Targeted Therapy.肾细胞癌中BRAF突变的罕见发现及对BRAF靶向治疗的反应
Cureus. 2016 Jan 6;8(1):e449. doi: 10.7759/cureus.449.
2
Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition.黑色素瘤：分子靶向治疗与免疫检查点抑制的交集。
Curr Opin Immunol. 2016 Apr;39:30-8. doi: 10.1016/j.coi.2015.12.006. Epub 2016 Jan 5.
3
Common reduction of the Raf kinase inhibitory protein in clear cell renal cell carcinoma.透明细胞肾细胞癌中Raf激酶抑制蛋白常见的减少情况。
Oncotarget. 2014 Sep 15;5(17):7406-19. doi: 10.18632/oncotarget.1558.
4
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond.靶向RAF激酶用于癌症治疗：BRAF突变型黑色素瘤及其他情况。
Nat Rev Cancer. 2014 Jul;14(7):455-67. doi: 10.1038/nrc3760.
5
Comprehensive molecular characterization of clear cell renal cell carcinoma.透明细胞肾细胞癌的全面分子特征分析。
Nature. 2013 Jul 4;499(7456):43-9. doi: 10.1038/nature12222. Epub 2013 Jun 23.
6
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.BRAF 抑制与转移性黑色素瘤患者中黑色素瘤相关抗原表达增强和更有利的肿瘤微环境相关。
Clin Cancer Res. 2013 Mar 1;19(5):1225-31. doi: 10.1158/1078-0432.CCR-12-1630. Epub 2013 Jan 10.
7
Vemurafenib: the first drug approved for BRAF-mutant cancer.威罗菲尼：首个获批准用于 BRAF 突变型癌症的药物。
Nat Rev Drug Discov. 2012 Nov;11(11):873-86. doi: 10.1038/nrd3847. Epub 2012 Oct 12.
8
BRAF mutations in metanephric adenoma of the kidney.肾脏后肾腺瘤中的 BRAF 突变。
Eur Urol. 2012 Nov;62(5):917-22. doi: 10.1016/j.eururo.2012.05.051. Epub 2012 Jun 9.
9
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma.一个 SUMOylation 缺陷的 MITF 种系突变易导致黑色素瘤和肾细胞癌。
Nature. 2011 Oct 19;480(7375):94-8. doi: 10.1038/nature10539.
10
Familial renal cell carcinoma from the Swedish Family-Cancer Database.从瑞典家族癌症数据库中发现的家族性肾细胞癌。
Eur Urol. 2011 Nov;60(5):987-93. doi: 10.1016/j.eururo.2011.05.031. Epub 2011 May 25.